BioAge Labs (BIOA) EBT (2023 - 2026)

BioAge Labs has disclosed EBT across 4 years of filings, most recently posting -$25.9 million for Q2 2026.

• In Q2 2026, EBT fell 20.16% year-over-year to -$25.9 million; the TTM figure through Jun 2026 stood at -$93.9 million (down 18.51% YoY), while the FY2025 annual figure was -$80.4 million, down 13.34% from the prior year.
• EBT came in at -$25.9 million for Q2 2026 at BioAge Labs, down from -$22.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$11.8 million in Q3 2023 to a low of -$25.9 million in Q2 2026.
• Average EBT over 4 years is -$18.9 million, with a median of -$20.8 million recorded in 2025.
• Year-over-year, EBT tumbled 95.92% in 2024 and climbed 12.87% in 2025.
• Over 4 years, EBT stood at -$15.8 million in 2023, then tumbled by 36.83% to -$21.6 million in 2024, then decreased by 19.17% to -$25.7 million in 2025, then fell by 0.67% to -$25.9 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$25.9 million in Q2 2026, -$22.1 million in Q1 2026, and -$25.7 million in Q4 2025.